Search

Search Constraints

You searched for: Issue Volume 93(2018)

Search Results

53. A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results. (April 2018)

56. A rapid assessment of co-benefits and trade-offs among Sustainable Development Goals. (July 2018)